Abstract:Abstract Background Angiopoietin-like protein 3 (ANGPTL3) is secreted by hepatocytes and inhibits lipoprotein lipase and endothelial lipase activity. Previous studies reported the correlation between plasma ANGPTL3 levels and high-density lipoprotein (HDL). Recently ANGPTL3 was found to preferentially bind to HDL in healthy human circulation. Here, we examined whether ANGPTL3, as a component of HDL, modulates HDL function and affects HDL other components in human and mice with non-diabetes or type 2 diabetes mellitus. Methods HDL was isolated from the plasma of female non-diabetic subjects and type-2 diabetic mellitus (T2DM) patients. Immunoprecipitation, western blot, and ELISA assays were used to examine ANGPTL3 levels in HDL. Db/m and db/db mice, AAV virus mediated ANGPTL3 overexpression and knockdown models and ANGPTL3 knockout mice were used. The cholesterol efflux capacity induced by HDL was analyzed in macrophages preloaded with fluorescent cholesterol. The anti-inflammation capacity of HDL was assessed using flow cytometry to measure VCAM-1 and ICAM-1 expression levels in TNF-α-stimulated endothelial cells pretreated with HDL. Results ANGPTL3 was found to bind to HDL and be a component of HDL in both non-diabetic subjects and T2DM patients. Flag-ANGPTL3 was found in the HDL of transgenic mice overexpressing Flag-ANGPTL3. ANGPLT3 of HDL was positively associated with cholesterol efflux in female non-diabetic controls (r = 0.4102, p = 0.0117) but not in female T2DM patients (r = − 0.1725, p = 0.3224). Lower ANGPTL3 levels of HDL were found in diabetic (db/db) mice compared to control (db/m) mice and were associated with reduced cholesterol efflux and inhibition of VCAM-1 and ICAM-1 expression in endothelial cells (p < 0.05 for all). Following AAV-mediated ANGPTL3 cDNA transfer in db/db mice, ANGPTL3 levels were found to be increased in HDL, and corresponded to increased cholesterol efflux and decreased ICAM-1 expression. In contrast, knockdown of ANGPTL3 levels in HDL by AAV-mediated shRNA transfer led to a reduction in HDL function (p < 0.05 for both). Plasma total cholesterol, total triglycerides, HDL-c, protein components of HDL and the cholesterol efflux function of HDL were lower in ANGPTL3−/− mice than ANGPTL3+/+ mice, suggesting that ANGPTL3 in HDL may regulate HDL function by disrupting the balance of protein components in HDL. Conclusion ANGPTL3 was identified as a component of HDL in humans and mice. ANGPTL3 of HDL regulated cholesterol efflux and the anti-inflammatory functions of HDL in T2DM mice. Both the protein components of HDL and cholesterol efflux capacity of HDL were decreased in ANGPTL3−/− mice. Our findings suggest that ANGPTL3 in HDL may regulate HDL function by disrupting the balance of protein components in HDL. Our study contributes to a more comprehensive understanding of the role of ANGPTL3 in lipid metabolism.

EDEM3 Modulates Plasma Triglyceride Level through Its Regulation of LRP1 Expression

Abstract 16650: EDEM3 Modulates the Plasma Triglyceride Level via Its Regulation of LRP1 Expression

506-P: Regulation of ANGPTL3 by SEL1L-HRD1 ER-Associated Degradation

Identifying the Lipidomic Effects of a Rare Loss-of-Function Deletion in ANGPTL3

Genetic Variants at PSMD3 Interact with Dietary Fat and Carbohydrate to Modulate Insulin Resistance

Genetic inhibition of angiopoietin-like protein-3, lipids, and cardiometabolic risk

Replication of a Gene-Diet Interaction at CD36, NOS3 and PPARG in Response to Omega-3 Fatty Acid Supplements on Blood Lipids: A Double-Blind Randomized Controlled Trial.

ANGPTL3 deficiency impairs lipoprotein production and produces adaptive changes in hepatic lipid metabolism

Erratum: A Rare Variant in APOC3 is Associated with Plasma Triglyceride and VLDL Levels in Europeans

Loss-of-Function CREB3L3 Variants in Patients With Severe Hypertriglyceridemia

Abstract 115: Angptl3 Deficiency Impairs Triglyceride-rich Lipoprotein Production and Produces Adaptive Changes in Hepatic Lipid Metabolism

New Insights into ANGPLT3 in Controlling Lipoprotein Metabolism and Risk of Cardiovascular Diseases

Endothelial lipase mediates efficient lipolysis of triglyceride-rich lipoproteins

Circulating exosomal circRNA-miRNA-mRNA network in a familial partial lipodystrophy type 3 family with a novel PPARG frameshift mutation c.418dup

Loss-of-function mutations in APOC3, triglycerides, and coronary disease.

Inactivation of ANGPTL3 reduces hepatic VLDL-triglyceride secretion

Integrin Β3 Deficiency Results in Hypertriglyceridemia Via Disrupting LPL (lipoprotein Lipase) Secretion

Leveraging Genetics to Address the Role of GALNT2 on Atherogenic Dyslipidemia

LINC317.5 as a novel biomarker for hypertriglyceridemia in normal glucose metabolism

ANGPTL3 is a novel HDL component that regulates HDL function

Association Analyses of East Asian Individuals and Trans-Ancestry Analyses with European Individuals Reveal New Loci Associated with Cholesterol and Triglyceride Levels